Pathologic fractures correlate with reduced survival in patients with malignant bone disease

Fred Saad(Centre Hospitalier de l’Université de Montréal), Robert E. Coleman(University of Sheffield)

Cancer

August 30, 2007

10.1002/cncr.22991

Cited by 658

Related Papers

Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer

|New England Journal of Medicine|2013|3.3k

Enzalutamide in Metastatic Prostate Cancer before Chemotherapy

|New England Journal of Medicine|2014|3k

Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy

|New England Journal of Medicine|2012|2.8k

Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study

|The Lancet Oncology|2012|1.4k

Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study

|The Lancet Oncology|2015|1.4k